
Index

- abbreviated new drug application 17
- adverse drug reactions (ADRs), **4**, 19, 24, 25, 33, 34/ 35, **37, 41, 42, 43, 45, 50, 51, 52**
 in Great Britain, **23-25, 38**
 in Japan, **23**
international monitoring, 44
 screening of (SOAR), **45**
- American Academy of Dermatology, 42
- authority for refusing application; approval of application, **57-58**
- Beta-Blocker Heart Attack Study Group, 51
- Birth Defects Monitoring Project (National Centers for Disease Control), **43**
- Boston Collaborative Drug Surveillance Program, **41, 42**
- Boston University Medical Center Drug Epidemiology Unit, 41, 42
- case studies in drug evaluation, **36-38**
- Center for Drug Surveillance, 60**
- Children's Hospital Medical Center (Boston, Mass.), 41, **42**
- cimetidine, 19, 37, 38, 42**
- Commission on Professional and Hospital Activities—
 Professional Activity Study (Ann Arbor, Mich.), 42
- Commission on the Federal Drug Approval Process, 5, **27, 49**
- compassionate IND, 15
- conclusions and recommendations of the Joint
 Commission on Prescription Drug Use, **59-60**
- Congress:
 acts of (see legislation)
 House Committee on Energy and Commerce,
 Subcommittee on Health and Environment, iii
 House Committee on Science and Technology:
 Subcommittee on Natural Resources, Agriculture
 Research and Environment, 6, **27**
Subcommittee on Investigations and Oversight,
6, 27
 Senate Committee on Labor and Human Resources,
 Subcommittee on Health, **5, 26**
- current activities that contribute to postmarketing surveillance, 41-45
- Department of Commerce, 5, **27**
- Department of Health, Education, and Welfare (now**
DHHS), 5
 Review Panel on New Drug Regulation, **26**
Secretary of, 14, 57-58
- diethylstilbestrol, 23, 33**
- Down's syndrome, 36
- drug approval process, 4-5, 13-19
- drug classification, **16**
- Drug Enforcement Agency, 44
- Dubin-Johnson syndrome, 36
- Experimental Technology Incentives Program (ETIP),
5, 27
- Food and Drug Administration (FDA) (Department of
 Health and Human Services), **3, 4, 5, 6, 7, 8, 9, 10,**
13, 14, 15, 16, 17, 18, 26, 27, 31, 37, 38, 41, 42,
43, 44, 45, 49, 50, 51, 52, 53, 54
 authority, 3, 4, 26, 27, 28, 49, 51, 52, 53, 54
 Bureau of Biologics, 6, 27
 Bureau of Drugs, 6, 27
 Current Drug Experience Literature, 45
 Division of Drug Experience, 42, 44
 National Center for Drugs and Biologics, 6, 27
 New Drug Evaluation Division, 6, 27
 monitoring questions, 45
 refusing application, 57-58
 removal of drugs, 53, 54
- General Accounting Office (GAO), 45, 52
- glossary of acronyms, ix
- Great Britain:
 adverse drug reactions, 23-25
 oral contraceptives, 36
 postmarketing surveillance, 23
 practolol syndrome, 23
 voluntary reporting system, 23
 yellow card, 23, 24-25, **31, 36**
- Group Health Cooperative of Puget Sound, 41, 42
- history and objectives of postmarketing surveillance,
 23-28
- Hoechst-Roussel Pharmaceuticals, 37
- improving postmarketing surveillance, 9-10, 51-54
- IND application process, 13
- investigational new drug (IND), 4, 5, 14, 15, 16
 clinical investigations:
 Phase I: Clinical pharmacology, 4, 9, 13, 14, 15, 17
 Phase II: Clinical investigations, 4, 6, 9, 13, 14, 15,
 27, 50
 Phase III: Clinical trials, 4, 5, 6, 8, 9, 10, 15, 17,
 18, 19, 27, 38, 49, 50, 53, 54
- issues and options, 8-10, 49-54
- Javits, Senator Jacob, 26
- Joint Commission on Prescription Drug Use, 5, 26, 49,
 51, 52
 conclusions and recommendations, 59-60
- Kennedy, Senator Edward, 5, 26
- legislation:
 Drug Regulation Reform Act of 1979 (S. 1075) (H. R.
 4258), 5, 26
 excerpts from statutes governing drugs and medical
 devices, 57-58

- Food, Drug, Cosmetic Act, 5, 14, 26
 Medical Device Amendments of 1976 (Public Law 94-295), 53, 54
 Patent Term Restoration Act of 1981 (S. 255), 6, 27, 49
 Senate Bill S. 1075, 5, 26, 53, 54
- Medicaid, 32, 42, 43, 52
 Medicaid Medical Information Systems, 4, 42
 Medicare, 32, 52
 methods of surveillance, 31-38
 Monthly Index of Medical Specialties, 23
- National Bureau of Standards (Department of Commerce), 5, 27
 National Cancer Institute, 13, 43
 National Center for Drugs and Biologics, 14
 Office of Drugs, 14, 15, 18, 19
 National Center for Drug Science, 5, 26, 49
National Center for Health Statistics, 43
 National Ambulatory Medical Care Survey, 43
 National Heart, Lung, and Blood Institute (NHLBI), 51
 National Institutes of Health, 45
 National Institute on Drug Abuse, 44
 National Registry of Drug-Induced Ocular Side Effects, 42
 new drug application process, 16
 New England Journal of Medicine, 51
- oral contraceptives, effects of 36, 37
 in Great Britain, 36
 in Sweden, 36
- Pharmaceutical Manufacturers Association, 5, 26
 practolol, 23
 propranolol, 9, 19, 50, 51
- Registry of Dermatological Reactions to Drugs, 42
 Registry of Hepatic Toxicity to Drugs, 42
 Registry of Patients Exposed to Radiopharmaceutical Drugs, 42
 Remington, R. D., 52
 requirements following new drug approval, 18-19
 Review Panel on New Drug Regulations, 5
 revising premarketing tests, 8-9, 49-51
- shortening the drug approval process, 8-9
 Smith, Kline & French Laboratories, 37
- Spontaneous Reaction Reporting Program, 4, 19
 streptokinase, 19, 37, 42
 surveillance:
 abbreviated new drug application (ANDA), 17
background incidence, 8, 32, 34, 35
benefit/risk ratio, 17
 clinical investigations (see investigational new drug)
 evidence of efficacy and safety, 3, 6
 grandfather drugs, 13
 history, 5
 imminent hazard to the public health, 3, 5, 10, 26, 54, 57
 international monitoring, 44
 manufacturer's programs, 41, 42
methods, 6-8
case-control studies, 6, 7, 8, 9, 10, 31, 32, 33, 36, 51
cohort studies, 6, 7, 8, 9, 10, 31, 32, 33, 36, 51
controlled clinical trials, 6, 7, 8, 9, 10, 17, 31, 32, 33, 35, 36, 38, 51
voluntary reporting, 6, 7, 10, 31, 32, 33, 37, 42, 45
 new drug application (NDA), 4, 5, 13, 14, 15, 16, 17, 18, 19
 nonapprovable letter, 17
 objectives, 5
 postmarketing, 3, 5, 6, 7, 9, 10, 18, 23, 26, 27, 28, 31, 37, 38, 41, 45, 49, 50, 51, 52, 53, 54, 59-60
 Phase IV, 18, 19, 42, 52
 principal focus, 3
 premarketing testing, 3, 4, 6, 8, 9, 13, 14, 18, 19, 26, 27, 28, 31, 37, 38, 49, 50, 52, 54
 removal of drug from market, 3
 sampling, 7, 8, 9, 33, 34, 35, 37, 38
 sponsor of drug, 4, 5, 13, 14, 16, 17, 18, 26, 37, 52
 substantial evidence, 13
 timolol, 9, 50, 51
 Norwegian study, 50-51
- Temple, Robert, 15
 thalidomide, 23
- World Health Organization (WHO), 4, 19, 41
 Program for International Monitoring of Adverse Reactions, 44
- yellow card (fig. 1), 24-25